Medicinal cannabis On January 8 2016, Germany’s Federal Ministry of Health released a bill that could change the country’s controlled substances legislation and grant patients access to cannabis. More detailed information about the draft can be found in this article.
On January 8 2016, Germany’s Federal Ministry of Health released a bill that could change the country’s controlled substances legislation and grant patients access to cannabis.
Better support for chronically ill
These proposed changes in the Narcotics Act (German: BtMG) would allow doctors to prescribe medicinal cannabis to patients. The medicine would be made available in pharmacies.
Another change would be the reimbursement of the costs for medicinal cannabis under certain circumstance such as that of patients suffering from a severe and chronic illness. However, patients wanting to apply for this reimbursement will need to agree to be part of a study, which will take place until the end of 2018. It will form the basis for further decisions, and possible rulings, when it comes to insurances reimbursing the costs of medicinal cannabis.
BfArM will become cannabis agency
This also means that patients would no longer need to apply for an exemption from the Federal Institute for Drugs and Medical Devices (German: BfArM) for the use of medicinal cannabis anymore. Up until October 1 2015, 527 German patients were granted such an exemption but have been obliged to cover all expenses linked to their medicinal cannabis.
In the future, this institute would function as a national cannabis agency according to the UN Single Convention. It would coordinate and control the cultivation, supply and quality of the medicinal cannabis. This agency would also be the authority responsible for determining the medicine’s price in pharmacies.
Private cultivation of cannabis is not an option
Within the draft, Germany’s Ministry of Health has left no alternative when it comes to sourcing the medicinal cannabis. It states the following:
“Private cannabis cultivation by patients is out of the question for regulative and health policy reasons.”
The ACM (German division of the International Association for Cannabinoid Medicines) reported that healthcare organizations, including ACM, have been invited to give their feedback on the draft until February 5th, 2016. It goes without saying that Sensi Seeds will keep the readership informed on this matter.
What do you think?
What do you think about this draft? We would like to hear from you, especially from cannabis patients. Share your thoughts with us by leaving a comment below.